中文
About Us
Corporate Overview
Management Team
Board of Directors
Contact Us
Our Focus
Viral Hepatitis
NASH
HIV/AIDS
Pipeline & Products
Pipeline
Products
Clinical Trials
Partnership
Investors
Financials & Filing
Presentation Materials
News
Careers
Investors
Financials & Filing
Presentation Materials
Next Day Disclosure Returns - Others
2021-01-14
Voluntary Announcement - Gannex Announces Positive Phase I Clinical Results on Its THR-beta Agonist ASC41
2021-01-12
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2020
2021-01-05
Grant of Share Options
2020-12-31
Voluntary Announcement - First Subject Dosed with Gannex's FXR Agonist ASC42 in a U.S. Phase I Trial
2020-12-28
Voluntary Announcement - Overweight and Obese Subjects Dosed with ASC41 Tablets in a Phase Ib Trial
2020-12-22
Next Day Disclosure Returns - Share Buyback
2020-12-14
Voluntary Announcement - Gannex Received U.S. FDA Fast Track Designation for Its NASH Drug Candidate ASC42, an FXR Agonist
2020-12-14
Next Day Disclosure Returns - Share Buyback
2020-12-04
Voluntary Announcement - ASC22 (Envafolimab) Is Safe and Well Tolerated in Phase IIa HBV Study and Phase IIb HBV Clinical Trial Has Been Initiated
2020-12-04
1
2
3
4
»